Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Long-Term Clinical Study of TS-071 as Monotherapy in Patients With Type 2 Diabetes Mellitus

Trial Profile

A Long-Term Clinical Study of TS-071 as Monotherapy in Patients With Type 2 Diabetes Mellitus

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 17 May 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Luseogliflozin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Taisho Pharmaceutical
  • Most Recent Events

    • 24 Mar 2016 Pooled analysis (n=1031) of 4 trials - JapicCTI111507, JapicCTI111508, JapicCTI111509, and JapicCTI111543 were published in the Clinical Therapeutics.
    • 02 Oct 2013 New source identified and integrated: Japan Pharmaceutical Information Center: JAPIC Clinical Trials Information.
    • 26 Sep 2013 Results reported at 49th Annual Meeting of the European Association for the Study of Diabetes (EASD), according to a Taisho Pharmaceutical Holdings media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top